The global antimicrobial resistance surveillance market is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period. Growth in this market is majorly driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies and growing government initiatives to combat antimicrobial-resistance species.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21323165
Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) – Global Forecast to 2028
The prominent players in this market are Becton, Dickinson and Company (US), Biomerieux (France), Thermo Fisher Scientific (US), Danaher (US), Luminex Corporation (US), Bruker (US), Merck KgaA (Germany), Bio-Rad (US), Qiagen (Germany), Abbott Laboratories (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Wolters Kluwer N.V. (US), Lumed (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Italy), and Bioanalyse (Turkey).
The global market for antimicrobial resistance surveillance is categorized into different solutions, including diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the dominant portion of this market is held by the diagnostic kits segment. This prominence is mainly a result of the growing need for swift and precise tools for identifying antimicrobial resistance. These diagnostic kits play a crucial role in identifying the existence of bacteria resistant to antimicrobial agents within clinical samples like blood, urine, and respiratory secretions.
Categorized by its applications, the global market for antimicrobial resistance surveillance is divided into clinical diagnostics, public health surveillance, and other uses. For the year 2023, it is projected that the clinical diagnostics segment will hold the most significant portion of the global antimicrobial resistance surveillance market. This expansion within the segment is linked to several factors, including the escalating occurrence of antimicrobial resistance, the imperative to enhance patient outcomes, the utility in determining bacteria’s susceptibility to diverse antimicrobial agents. This information is crucial for healthcare providers to make well-informed choices regarding the treatment of patients afflicted with infections resistant to antimicrobial treatments.
Categorized by their end users, the global market for antimicrobial resistance surveillance is divided into hospitals & clinics, research and academic institutes, and other entities. For the year 2023, it is anticipated that the hospitals & clinics segment will hold the most substantial portion of the global antimicrobial resistance surveillance market. The prevalence of this segment can be attributed to its crucial role at the frontline of patient care, infection management, and data generation. Furthermore, hospitals & clinics are obligated to undertake surveillance of antimicrobial resistance as an integral part of their operations.
Categorized by geographical regions, the antimicrobial resistance surveillance market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. In the year 2023, it is projected that the North American sector of the antimicrobial resistance surveillance market will hold the most significant portion. This prominence can be ascribed to several factors, including the existence of prominent market participants, heightened consciousness regarding antimicrobial resistance surveillance, and a robust regulatory framework.
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
The threat of antibiotic-resistant bacteria, often referred to as “superbugs,” is a growing global health crisis. As these resilient pathogens continue to evade our most potent antimicrobial weapons, the need for robust surveillance systems has become increasingly critical. This emerging market is poised to play a vital role in monitoring and containing the spread of these formidable foes.
Valued at $5.9 billion in 2023, the antimicrobial resistance (AMR) surveillance market is projected to reach $7.7 billion by 2028, growing at an impressive compound annual growth rate (CAGR) of 5.6%. Driven by the rising prevalence of infections caused by drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and carbapenem-resistant Enterobacteriaceae (CRE), this market is poised to provide invaluable solutions for healthcare providers and public health authorities.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21323165
Diagnostic kits and systems lie at the heart of this market, enabling rapid and accurate detection of antimicrobial-resistant bacteria in clinical samples. With hospitals and clinics being the primary battlegrounds against these resilient foes, these facilities are expected to be the largest consumers of AMR surveillance solutions.
North America currently dominates the AMR surveillance market, buoyed by the presence of leading market players, the highest prevalence of antimicrobial resistance, and a robust regulatory environment. However, emerging economies in Asia Pacific, Latin America, and the Middle East are poised to become significant growth drivers, presenting untapped opportunities for companies in this domain.
Despite the promising prospects, the AMR surveillance market faces challenges. The high cost of diagnostic systems and kits can be a barrier for widespread adoption, particularly in resource-limited settings. Academic research laboratories and smaller healthcare facilities may struggle to afford these cutting-edge solutions. Additionally, complex regulatory frameworks and the time lag between establishing clinical breakpoints and approving new antimicrobial agents can hinder the timely integration of the latest developments into surveillance programs.
Prominent players in the AMR surveillance market include Luminex Corporation, Thermo Fisher Scientific, BioSpace, Cepheid, Accelerate Diagnostics, Inc., Liofilchem S.r.l., Becton, Dickinson and Company, bioMérieux, Bruker, Danaher, Merck KGaA, Bio-Rad, Qiagen, Abbott Laboratories, Roche Diagnostics, OpGen, Inc., Wolters Kluwer N.V., Lumed, Alifax S.r.l., and Bioanalyse. These companies are at the forefront of developing cutting-edge solutions to combat the ever-evolving threat of antimicrobial resistance.
As the battle against superbugs intensifies, the antimicrobial resistance surveillance market stands as a crucial line of defense, providing the tools and technologies necessary to monitor, detect, and ultimately confront these formidable adversaries. With continued innovation and strategic partnerships, this market has the potential to fortify our defenses and safeguard public health on a global scale.